These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27769054)

  • 1. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.
    Hale MD; Nankivell M; Hutchins GG; Stenning SP; Langley RE; Mueller W; West NP; Wright AI; Treanor D; Hewitt LC; Allum WH; Cunningham D; Hayden JD; Grabsch HI
    Oncotarget; 2016 Nov; 7(47):77565-77575. PubMed ID: 27769054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
    Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
    Davarzani N; Hutchins GGA; West NP; Hewitt LC; Nankivell M; Cunningham D; Allum WH; Smyth E; Valeri N; Langley RE; Grabsch HI
    Histopathology; 2018 Jun; 72(7):1180-1188. PubMed ID: 29465751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
    Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial.
    Davarzani N; Hewitt LC; Hale MD; Melotte V; Nankivell M; Hutchins GGA; Cunningham D; Allum WH; Langley RE; Jolani S; Grabsch HI
    Dis Esophagus; 2020 Aug; 33(8):. PubMed ID: 32591823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
    Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
    Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
    Liu DHW; Šefčovičová N; Emmerson J; Spaans LN; Saito Y; Hutchins G; Nankivell MG; Langley RE; Allum W; Cunningham D; Langer R; Grabsch HI
    Eur J Cancer; 2022 Jul; 170():140-148. PubMed ID: 35635935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology.
    De Cobelli F; Giganti F; Orsenigo E; Cellina M; Esposito A; Agostini G; Albarello L; Mazza E; Ambrosi A; Socci C; Staudacher C; Del Maschio A
    Eur Radiol; 2013 Aug; 23(8):2165-74. PubMed ID: 23588582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.
    Boonstra JJ; Kok TC; Wijnhoven BP; van Heijl M; van Berge Henegouwen MI; Ten Kate FJ; Siersema PD; Dinjens WN; van Lanschot JJ; Tilanus HW; van der Gaast A
    BMC Cancer; 2011 May; 11():181. PubMed ID: 21595951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
    Geh JI; Glynne-Jones R; Kwok QS; Banerji U; Livingstone JI; Townsend ER; Harrison RA; Mitchell IC
    Clin Oncol (R Coll Radiol); 2000; 12(3):182-7. PubMed ID: 10942336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
    Dunne B; Reynolds JV; Mulligan E; Kelly A; Griffin M
    J Clin Pathol; 2001 Nov; 54(11):841-5. PubMed ID: 11684717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone.
    Ancona E; Ruol A; Santi S; Merigliano S; Sileni VC; Koussis H; Zaninotto G; Bonavina L; Peracchia A
    Cancer; 2001 Jun; 91(11):2165-74. PubMed ID: 11391598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
    Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
    Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
    Melcher AA; Mort D; Maughan TS
    Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer.
    Urschel JD; Vasan H; Blewett CJ
    Am J Surg; 2002 Mar; 183(3):274-9. PubMed ID: 11943125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.